Renal Cancer - Results from #620

Multimodal deep learning for personalized renal cell carcinoma prognosis: Integrating CT imaging and clinical data. December 21, 2023

Diversity in Renal Mass Data Cohorts: Implications for Urology AI Researchers. December 20, 2023

Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART). December 20, 2023

Real-World Treatment Patterns and Effectiveness of Patients With Advanced Renal Cell Carcinoma: A Nationwide Observational Study. December 19, 2023

Molecular Characterization of TFE3-rearranged Renal Cell Carcinoma, A Comparative Study with Papillary and Clear Cell Renal Cell Carcinomas. December 19, 2023

Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence. December 18, 2023

Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. December 18, 2023

FDA Approves Merck’s WELIREG® (Belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI December 16, 2023

PD-1 Expression on Intratumoral Regulatory T Cells is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear Cell Renal Cell Carcinoma Patients. December 15, 2023

Downregulation of Glycine N-Acyltransferase in Kidney Renal Clear Cell Carcinoma: A Bioinformatic-Based Screening. December 15, 2023

Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study. December 14, 2023

CD56 polysialylation promotes the tumorigenesis and progression via the Hedgehog and Wnt/β-catenin signaling pathways in clear cell renal cell carcinoma. December 14, 2023

Safety and Efficacy of Second-Line TKI Plus Anti-PD1 in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study. December 13, 2023

Perioperative and Survival Outcomes of Patients Treated With Robot-Assisted Partial Nephrectomy and Percutaneous Microwave Ablation for Small Renal Masses: A Single Center Experience. December 13, 2023

Adjuvant immunotherapy for locally advanced renal cell carcinoma. December 12, 2023

Interobserver reproducibility of RENAL nephrometry score in comparison to simplified PADUA Renal nephrometry score. December 12, 2023

Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune Phenotype. December 11, 2023

Thermal Ablation Versus Partial Nephrectomy for cT1 Renal Mass in a Solitary Kidney: A Matched Cohort Comparative Analysis. December 11, 2023

EHD2, a novel HIF target gene, is a promising biomarker in clear cell renal cell carcinoma. December 8, 2023

Identification of Crotonylation Metabolism Signature Predicting Overall Survival for Clear Cell Renal Cell Carcinoma. December 8, 2023

Page 32 of 457